A preclinical biotech company based in Wilmington, Delaware, focused on developing CAR‑T cell immunotherapies to treat severe allergic conditions. Founded in 2022, the company leverages novel CAR‑T ...

A biotech company spun-out from Aditum Bio and Leads Biolabs, with the aim to develop LBL-051, a first-in-class T-cell engager antibody for autoimmune diseases. The company was launched by Aditum Bio ...

A precision-oncology company developing small-molecule therapies to restore function of mutant forms of the tumor suppressor protein p53. The lead candidate is rezatapopt (PC14586), which is designed ...

A clinical-stage biopharma company based in Shanghai, China, develoing novel antibody therapies targeting immune checkpoints and other tumor-related pathways. Founded in 2019, the company leverages ...

Among significant news last week, Halozyme Therapeutics struck a license agreement for its INCA033989 with fellow USA-based ...

ExxPharma is a privately-held, New Jersey-based drug delivery and product development company. The company provides development and manufacturing services to discovery companies, and partners with ...

TauRx was built on Professor Claude Wischik's original identification of tau tangles as the lesion most tightly correlated with cognitive decline in Alzheimer's disease — predating the amyloid ...

A Chinese biotech company developing gene therapy drugs, most of which are targeted at beta thalassemia, AIDS, hemophilia and Parkinson's disease. In November 2024, Kanglin announced the successful ...

The US unit of Japan’s Otsuka (TYO: 4578) has been granted US Food and Drug Administration (FDA) approval for Simtriyo (centanafadine), a once-daily extended-release capsule for the treatment of ...

A UK-headquartered clinical-stage biopharmaceutical company developing once-weekly oral GLP-1 and amylin analogs for obesity ...

A San Francisco-based biotech company developing therapies that address age-related diseases. Founded in 2021 by Joe Betts-LaCroix and initially funded with $180 million from OpenAI CEO Sam Altman, ...

A clinical-stage immunology company based in the United States, operating within the Boston biotechnology ecosystem. Poplar Therapeutics was previously known as Phylaxis Bioscience and was ...